* Q1 NAV beat * Strong performance, higher valuations in private assets * P/NAV dislocation persists...
* Q1 sales SEK 13m, adj. EBIT SEK -16m (vs. ABGSCe 8m & -12m) * Softer quarter; no machine deliverie...
Overall, Absolent is showing continued progress with 7% organic top-line growth and improving margin...
Redeye retains its positive view of Addnode despite a relativley soft Q1 report.
The Q1 report came in slightly below our projections showing organic growth of 11% in local currenci...
Bet-at-home recently published its final FY25 figures.
Redeye returns with a research update after Elicera's Q1 update and announced rights issue.
* +9% organic growth y-o-y, +1% vs. ABGSCe * 19% adj.
Raute reports Q1 results on May 7. Earnings will decline this year from the high comparison period, ...
Solteq reported a weak Q1, with both revenue and earnings below estimates.
Oriola posted fairly decent figures in Q1. Net sales and invoicing growth continued at a good pace, ...
We hosted tonies at our Madrid conference. The key takeways fully underpin our positive view on the ...
* 8%/6% adj. EBITDA vs ABGSCe/Infront cons in Q1 * Cons estimates likely up 1-3% on adj.
Redeye updates its view on Hacksaw following stronger-than-expected Q1 results, driven by operationa...
Redeye comments positively on Litium’s Q1 2026 report, which beat our estimates on every key metric.
* EEs +7%, sales +8%, adj. EBIT +53% vs. ABGSCe * Stronger EBIT driven by series production and mild...
RaySearch came in softer than we expected on sales and EBIT (but in line with consensus EBIT).
Redeye’s initial take on Sleeps Cycles' Q1 report confirms the company remains on track with its 202...
Taaleri’s Q1 2026 continuing earnings of EUR 10.5m increased by 13% y/y and came 6% above our estima...
Redeye provides its initial take on MedCap’s Q1 2026 report, which came in broadly in line with our ...
